Eris Lifesciences logo

Eris Lifesciences

ERIS NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹18,698 Cr
Volatility
Moderate
P/E Ratio
28.99
EBITDA
₹1,128 Cr
Return on Equity
16.62%
Debt to Equity
0.6
Book Value
₹281.61
EPS
₹27.95
52W High
₹1,745
52W Low
₹1,200

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Weaknesses

2
  • Stock is trading at 4.81 times its book value
  • Tax rate seems low

Growth Rate

Revenue Growth
7.73% lower than 3Y
Net Income Growth
72.8% higher than 3Y
Cash Flow Change
-49.48% lower than 3Y
ROE
45.15% higher than 3Y
ROCE
23.39% lower than 3Y
EBITDA Margin (Avg.)
1.1% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk medium

ERIS Lifesciences, with a market cap of ₹18,698 Cr and a PE of 28.2x, is a mid-cap specialty pharma company that has delivered 23% compounded sales growth over 3 years and 69% TTM profit growth. ROE stands at 19% for the last year, while the stock has declined 20% over the past 1 year despite solid underlying earnings expansion.

Bull Case 7
  • Strong TTM profit growth of 69% indicates a significant jump in earnings, suggesting operating leverage or margin expansion kicking in
  • Compounded sales CAGR of 23% over 3 years and 21% over 5 years reflects consistent above-industry revenue growth
  • Last year ROE of 19% and 5-year average ROE of 18% demonstrate sustained capital efficiency well above cost of equity for most pharma companies
  • 10-year compounded sales CAGR of 18% shows a long track record of durable revenue growth across market cycles
  • 10-year compounded profit CAGR of 17% alongside 10-year average ROE of 21% indicates the business has historically generated strong shareholder returns
  • Stock has corrected 20% over the past 1 year despite strong earnings growth, meaning valuations have compressed from prior peaks
  • Dividend yield of 0.53% while modest, indicates the company returns some cash to shareholders even while investing in growth
Bear Case 8
  • PE ratio of 28.2x is elevated for a pharma company with 10% TTM sales growth, implying the market is pricing in acceleration that may not materialize
  • Stock trades at 4.82x book value, which is rich and leaves limited margin of safety if growth slows
  • 1-year stock CAGR of -20% signals that the market has been de-rating the stock despite earnings growth, possibly reflecting concerns not visible in headline numbers
  • Tax rate flagged as seemingly low, which could mean current earnings are inflated by tax benefits that may normalize over time, compressing net profit
  • TTM sales growth has decelerated to 10% compared to 23% 3-year CAGR and 21% 5-year CAGR, suggesting a potential slowdown in topline momentum
  • 5-year compounded profit CAGR of only 12% versus 21% sales CAGR over the same period indicates profits have historically lagged revenue growth, raising margin sustainability questions
  • 3-year ROE of 16% is lower than the 10-year average of 21%, suggesting returns on equity have been trending downward from peak levels
  • Debt-to-equity and ROCE data are unavailable, limiting visibility into the company's leverage and true capital efficiency

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Neutral 4
  • ₹45Cr term loan from Axis Bank Sep 9

    Eris Lifesciences secured a ₹45 crore term loan from Axis Bank to meet other liabilities. The company stated this routine adjustment will not impact its expected net debt figure at quarter-end.

  • FY26 BRSR report filed Sep 2

    Eris submitted its Business Responsibility and Sustainability Report for FY26, covering environmental metrics, workforce data, and governance disclosures for standalone India operations.

  • Independent director reappointed Aug 31

    Board reappointed Sujesh Vasudevan as independent director for five years. The 20th AGM is scheduled for September 25, 2026.

  • Investor meets with fund houses Sep 7

    Eris scheduled investor meetings with Bank of India Mutual Fund on Sep 10 and HBM Partners AG on Aug 27, represented by senior management including Amit Bakshi and Krishnakumar Vaidyanathan.

TL;DR: A quiet period for Eris Lifesciences with no material positive or negative catalysts. Activity is limited to routine corporate governance actions, a small ₹45 crore term loan described as having no impact on net debt, and standard investor engagement. No operational or strategic red flags, but also no growth triggers visible in this news cycle. Watch for any updates around the Sep 25 AGM for forward-looking commentary.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
467
505
486
551
720
741
727
705
773
792
807
757
873
Expenses
297
324
311
402
470
477
477
453
496
504
526
484
577
Operating Profit
170
181
176
148
250
265
250
252
277
288
282
272
296
OPM %
36%
36%
36%
27%
35%
36%
34%
36%
36%
36%
35%
36%
34%
Other Income
1
3
4
15
2
5
4
8
4
3
-17
2
2
Interest
17
16
18
33
60
59
57
54
49
50
49
46
47
Depreciation
41
42
46
54
76
80
81
77
71
69
70
70
72
PBT
112
126
116
77
116
129
116
129
161
173
145
159
179
Tax %
17%
3%
12%
-4%
22%
25%
25%
21%
22%
22%
25%
-75%
20%
Net Profit
94
122
101
80
90
96
87
102
125
134
109
279
143
EPS in Rs
6.98
9.07
7.55
5.22
6.12
6.73
6.15
6.89
8.66
8.82
7.32
20.33
10.28
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
546
597
750
856
982
1,074
1,212
1,347
1,685
2,009
2,894
3,129
3,230
Expenses
427
425
480
533
637
702
781
858
1,146
1,332
1,876
2,009
2,092
Operating Profit
118
172
269
322
345
372
431
489
539
677
1,018
1,120
1,138
OPM %
22%
29%
36%
38%
35%
35%
36%
36%
32%
34%
35%
36%
35%
Other Income
7
3
25
26
31
12
9
22
9
22
18
-9
-9
Interest
0
0
1
11
23
2
2
4
26
85
231
193
191
Depreciation
16
20
23
26
36
50
43
65
117
183
315
280
281
PBT
109
154
270
312
317
331
394
442
405
431
489
639
657
Tax %
18%
13%
9%
6%
8%
11%
10%
8%
8%
8%
23%
-1%
—
Net Profit
89
135
247
295
291
297
355
406
374
397
375
648
666
EPS in Rs
6,489
9,714
17.95
21.39
21.15
21.84
26.16
29.88
28.1
28.82
25.84
44.72
46.75
Div. Payout %
0%
63%
0%
0%
0%
13%
21%
20%
26%
0%
28%
16%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.14
0.14
14
14
14
14
14
14
14
14
14
14
Reserves
266
299
553
848
1,137
1,283
1,563
1,895
2,182
2,573
2,841
3,889
Borrowings
1
0
1
377
176
0
7
84
877
2,781
2,478
2,359
Other Liabilities
91
98
124
170
175
205
202
233
337
1,366
1,415
861
Total Liabilities
357
397
692
1,408
1,502
1,502
1,785
2,226
3,410
6,734
6,747
7,123
Fixed Assets
72
71
232
771
761
875
854
918
2,568
4,319
5,306
5,188
CWIP
0
0
0
0
3
4
2
27
22
20
67
171
Investments
167
190
303
365
356
78
294
520
37
16
67
62
Other Assets
119
136
157
271
383
544
636
761
783
2,379
1,307
1,702
Total Assets
357
397
692
1,408
1,502
1,502
1,785
2,226
3,410
6,734
6,747
7,123
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
90
131
200
235
223
271
375
378
292
486
1,065
538
Investing
-92
-44
-184
-590
-5
123
-323
-320
-975
-1,828
-78
-369
Financing
0
-84
-24
363
-221
-335
-82
-45
688
1,380
-881
-314
Net Cash Flow
-2
4
-8
8
-3
60
-30
14
5
38
105
-145
Free Cash Flow
77
108
150
210
186
125
350
258
-550
357
910
241
CFO/OP
96
97
94
94
85
87
103
94
68
87
114
59
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
16
16
24
28
31
53
42
44
63
77
58
79
Inventory Days
223
178
195
178
196
148
145
166
136
182
171
200
Days Payable
142
92
134
247
200
213
157
166
129
210
170
151
Cash Conversion Cycle
97
102
84
-40
28
-12
30
44
70
48
59
129
Working Capital Days
15
9
23
-13
-17
59
64
75
50
-296
-49
-71
ROCE %
47%
53%
60%
34%
26%
25%
27%
25%
17%
11%
12%
14%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Eris Lifesciences insights

66 extracted metrics + investor summaries across FY11–FY27.

Log in — free

Shareholding Pattern

FIIs5.75%Promot.54.14%Others9.29%Public10.10%DIIs20.72%As ofJun 2026
16.85% of promoter holding pledged as of Jun 2026

Documents

Frequently Asked Questions about Eris Lifesciences

What does ERIS Lifesciences Ltd do?
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]
Where is ERIS Lifesciences Ltd (ERIS) listed?
ERIS Lifesciences Ltd trades as ERIS on the NSE and under code 540596 on the BSE.
Which sector does ERIS Lifesciences Ltd belong to?
ERIS Lifesciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd has a market capitalisation of ₹18,698 Cr, which places it in the Mid Cap band.
What is the PE ratio of ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd trades at a PE ratio of 28.99, on earnings per share of ₹27.95, against a book value of ₹281.61 per share.
What is the 52-week high and low of ERIS Lifesciences Ltd?
Over the last 52 weeks ERIS Lifesciences Ltd has traded between ₹1,200 and ₹1,745.
Does ERIS Lifesciences Ltd pay dividends?
ERIS Lifesciences Ltd has a dividend yield of 0.53%.
What is the Return on Equity (ROE) of ERIS Lifesciences Ltd?
ERIS Lifesciences Ltd reported a return on equity of 16.62%. Its debt-to-equity ratio is 0.60.

Company Information

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

Website eris.co.in
CEO Mr. Amit Indubhushan Bakshi
Employees 3,354
Listed 2017-06-29
Face Value ₹ 1
Issued Size 13,62,16,891

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ERIS.md for ERIS Lifesciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List